UroGen CFO Degnan files Form 144 for 2,202 URGN shares
UroGen Pharma CFO Chris Degnan filed a Form 144 with the SEC indicating an intention to sell 2,202 restricted URGN shares, registered on 10/9/2026, with an approximate sale date of 10/8/2026.
UroGen Pharma CFO Chris Degnan filed a Form 144 with the SEC indicating an intention to sell 2,202 restricted URGN shares, registered on 10/9/2026, with an approximate sale date of 10/8/2026.